SCHEMBL2673155

SCHEMBL2673155

O=C1NC(=O)N(Cc2ccccc2)C(=O)C1Cc1cccc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.51
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
CASP6 P55212 1/20 0.44
GAA P10253 3/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 3/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 5/20 0.42
SIGMAR1 Q99720 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GLA P06280 2/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
HSD17B2 P37059 1/20 0.42
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7844009 0.87 EP300 (0.66) EP300KMT2AMEN1GAAPOLB
SCHEMBL2673297 0.87 MAPT (0.45) EP300KMT2AMEN1CYP2C9CYP3A4
SCHEMBL17717902 0.86 EP300 (0.56) EP300KMT2AMEN1GAAPOLB
SCHEMBL2672822 0.84 MAPT (0.42) EP300KMT2AMEN1CYP2C9CYP3A4
SCHEMBL2672856 0.83 ALDH1A1 (0.51) KMT2AMEN1GAACYP3A4MAPT
SCHEMBL3132028 0.83 ALDH1A1 (0.51) KMT2AMEN1GAACYP3A4MAPT
SCHEMBL2672873 0.81 HSD17B2 (0.43) KMT2AMEN1CYP2C9CYP3A4MAPT
SCHEMBL10048420 0.80 EP300 (0.56) EP300KMT2AMEN1GAAPOLB
SCHEMBL17717953 0.79 EP300 (0.48) EP300KMT2AMEN1GAAPOLB
SCHEMBL14656853 0.77 EP300 (0.51) EP300KMT2AMEN1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
EP-1778236-B1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS INC (US) 2010-07-14 EP disclosed
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2009-11-05 US disclosed
US-7576076-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2009-08-18 US disclosed
EP-1778236-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS Corcept Therapeutics, Inc. (US) 2007-05-02 EP disclosed
WO-2006014394-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2006-02-09 WO disclosed
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators NR3C1, NR3C2, TYMS EP300 1636/4885KMT2A 2535/4885MEN1 4371/4885
US-20090275600-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS NR3C1, NR3C2, TYMS EP300 1636/4885KMT2A 2535/4885MEN1 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.